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Abstract
Background: The most abundant cells in the extensive desmoplastic stroma of pancreatic adenocarcinomas are
the pancreatic stellate cells, which interact with the carcinoma cells and strongly influence the progression of the
cancer. Tumor stroma interactions induced by IL-1α/IL-1R1 signaling have been shown to be involved in pancreatic
cancer cell migration. TGFβ and its receptors are overexpressed in pancreatic adenocarcinomas. We aimed at
exploring TGFβ and IL-1α signaling and cross-talk in the stellate cell cancer cell interactions regulating pancreatic
adenocarcinoma cell migration.
Methods: Human pancreatic stellate cells were isolated from surgically resected pancreatic adenocarcinomas and
cultured in the presence of TGFβ or pancreatic adenocarcinoma cell lines. The effects of TGFβ were blocked by
inhibitors or amplified by silencing the endogenous inhibitor of SMAD signaling, SMAD7. Pancreatic stellate cell
responses to IL-1α or to IL-1α-expressing pancreatic adenocarcinoma cells (BxPC-3) were characterized by their
ability to stimulate migration of cancer cells in a 2D migration model.
Results: In pancreatic stellate cells, IL-1R1 expression was found to be down-regulated by TGFβ and blocking of
TGFβ signaling re-established the expression. Endogenous inhibition of TGFβ signaling by SMAD7 was found to
correlate with the levels of IL-1R1, indicating a regulatory role of SMAD7 in IL-1R1 expression. Pancreatic stellate
cells cultured in the presence of IL-1α or in co-cultures with BxPC-3 cells enhanced the migration of cancer cells.
This effect was blocked after treatment of the pancreatic stellate cells with TGFβ. Silencing of stellate cell expression
of SMAD7 was found to suppress the levels of IL-1R1 and reduce the stimulatory effects of IL-1α, thus inhibiting the
capacity of pancreatic stellate cells to induce cancer cell migration.
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Conclusions: TGFβ signaling suppressed IL-1α mediated pancreatic stellate cell induced carcinoma cell migration.
Depletion of SMAD7 upregulated the effects of TGFβ and reduced the expression of IL-1R1, leading to inhibition of
IL-1α induced stellate cell enhancement of carcinoma cell migration. SMAD7 might represent a target for inhibition
of IL-1α induced tumor stroma interactions.
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Background
Pancreatic ductal carcinoma (PDAC) is a highly lethal
disease, which usually has metastasized before diagnosis
[1]. Surgical resection, the only potentially curative treat-
ment, is only possible in 15–20 % of the patients [1, 2].
The disease is also largely resistant to chemotherapy and
radiotherapy [1]. Despite important advances in the un-
derstanding of the pathobiology of this cancer over the
last few decades [3], no real improvements in the clinical
outcome have been achieved, and the 5-year survival
rate is still less than 5 % [4, 5].
Many lines of evidence have demonstrated the crucial
role of the microenvironment of tumors [6]. Malignant
cells interact with a variety of stromal cell types and extra-
cellular matrix components, in complex manners closely
related to inflammatory processes [7]. These interactions
are mediated by a number of growth factors, cytokines, and
other locally active molecules, which exert fundamental in-
fluences on the properties of the cancer, such as its growth
rate and propensity to invade and metastasize [7, 8]. In
pancreatic tumors, a characteristic feature is the extensive
desmoplastic reaction consisting of extracellular matrix
(ECM) and stromal cells, sometimes comprising up to
90 % of the total tumor mass [9]. It is now clear that the
cells responsible for the desmoplastic reaction are a special
type of cancer-associated fibroblasts, the pancreatic stellate
cells (PSCs) [8, 10]. In the normal pancreas, they are quies-
cent, lipid-storing cells, however, in pancreatic injury or
stress, the PSCs can be activated by cytokines and other
factors released from injured ductal epithelium and stromal
cells and undergo transdifferentiation to myofibroblast-like
cells [11]. These activated PSCs have proliferative capacity
and ability to produce ECM and several tumor-promoting
growth factors [10]. The PSCs have been strongly impli-
cated in the progression of pancreatic cancer [12], and
evidence suggests that they function in a reciprocal stimu-
latory interaction with the carcinoma cells through various
active factors [13, 14]. However, this view has recently been
challenged by experimental data from genetically engi-
neered mice, showing that depletion of stromal compo-
nents enhanced tumor growth in pancreatic carcinomas
[15]. These discrepant results [9, 12–16], probably reflect
an even more complex tumor-stroma relationship than has
been recognized.
The interaction between pancreatic carcinoma and stel-
late cells largely takes place through various active factors.
Two of these factors are interleukin 1α (IL-1α) and trans-
forming growth factor beta (TGFβ) [17]. IL-1α is a highly
proinflammatory cytokine, abundantly present in the
tumor microenvironment, where it is released from
various stromal cells as well as from carcinoma cells [18].
Acting via its receptor IL-1R1, which belongs to the
interleukin-1 receptor/Toll-like receptor superfamily [19],
IL-1α exerts multiple effects in the tumor stroma, several
of which are tumor-promoting [20]. In pancreatic carci-
noma, IL-1α was found to sustain the expression of in-
flammatory factors in the microenvironment and enhance
the migratory capacity of the cancer cells [21]. Since
mutation of KRAS is a crucial event in pancreatic carcino-
genesis [22], it is of particular interest that studies in a
mouse model have strongly suggested that IL-1α is a link
between mutated, oncogenic Ras (KrasG12D) and the
tumor-promoting inflammatory microenvironment re-
quired for the development of these cancers [23].
TGFβ exerts profound, pleiotropic, context-dependent
regulations of normal and malignant cells [24–26]. Its
many effects in normal physiology include inhibitory
control of normal epithelial cell growth and regulation
of the immune system [27, 28]. In malignancy, TGFβ has
several and multifaceted roles. It exerts suppressive
effects on tumor-promoting inflammation and on early
stages of carcinogenesis, but, on the other hand, TGFβ is
a major factor enhancing tumor progression, epithelial-
mesenchymal transition (EMT), and invasiveness and
metastatic capacity [24, 28, 29]. The canonical TGFβ
signaling cascade involves binding and recruitment of cell
surface kinase receptors (TβRII and TβRI) and intracellu-
lar activation of SMAD2 or SMAD3 proteins which form
a complex with SMAD4 and subsequently translocate
into the nucleus, interacting with other transcription fac-
tors to regulate the expression of target genes. The TGFβ/
SMAD signaling cascade is regulated by endogenous in-
hibitors, SMAD6 and SMAD7 [24, 25]. Although TGFβ
preferably signals via the SMAD pathway, it can also acti-
vate other pathways that collectively are referred to as
non-canonical TGFβ signaling which complements the
action of SMAD [26]. In pancreatic cancer, the effects of
TGFβ are complex and not fully understood [30]. In
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particular, the role of TGFβ in signal cross-talk between
carcinoma cells and pancreatic stellate cells is of interest
for identification of targets for novel therapeutic strategies
and warrants further study. In the present work we have
studied effects of IL-1α and TGFβ in stromal cell-induced
migration of pancreatic carcinoma cells. The data show
that TGFβ signaling suppressed IL-1α-mediated stellate
cell-induced carcinoma cell migration, indicating that




The study protocol and patient consent documents were
approved by the Regional Committee for Medical and
Health Research Ethics (REC South East, project number
2010/694a), and was in compliance with the Helsinki
Declaration. Written informed consent was obtained from
all study participants. The study included only adults.
Cells, isolation and culture
Human pancreatic stellate cells (PSCs) were isolated from
pancreatic tumor tissue obtained during pancreatic surgery
from patients with resectable pancreatic head adenocarci-
noma and cultured by the outgrowth method developed
by Bachem et al. [31] as explained elsewhere [32]. The
purity of the PSCs was assessed by morphology and cytofi-
lament staining of α-SMA and vimentin. None of the cells
were positive for CK7 or CK20. All experiments were
performed using cell populations between passage 4 and 8.
The primary PDAC cell line PC013 was propagated from
PDAC tumor tissue biopsies as described elsewhere [21].
BxPC-3 and CAPAN2 were purchased from ATCC
(Manassas, VA, USA). All cell lines were cultured in
Dulbecco’s modified Eagle’s medium containing 4.5 g/l
glucose (DMEM). The media were supplemented with
100 μg/ml Pen-Strep, Glutamax and 10 % fetal bovine
serum (FBS) (Life Technologies). For IL-1α (Biolegend,
Sandiego, CA), IL-1RA (Kineret® (Anakinra) a gift from
Swedish Orphan Biovitrum AS, Norway), TGFβ and PDGF
(R&D Systems Europe, Abingdon, UK) stimulation, the
PSCs were cultured to confluence, washed with NaCl and
cultured in serum free (SF) DMEM medium supplemented
with 1 ng/ml IL-1α, and/or 2 ng/ml TGFβ, 10 μg/ml IL-
1Ra or 10 ng/ml PDGF. Supernatants were harvested after
4 days of culture, centrifuged and stored at −30 °C until
use. TGFβ signaling in PSCs were blocked by the ALK-5
inhibitor A-83-01 (5 μM) (R&D Systems) or the SMAD3
inhibitor SIS3 (Sigma-Aldrich, Oslo, Norway) (5 μM) in
the presence of 2 ng/ml TGFβ or conditioned medium
from BxPC-3, CAPAN2 or PC013 cells cultured in serum
free conditions for 3 days. All gene expression experi-
ments were conducted for 72 h before lysing the cells,
while PSC supernatants were harvested after 4 days of
culture and stored in −30 °C until use.
Gene silencing of SMAD7 by siRNA
Expression of SMAD7 was silenced using SMARTpool:
ON-TARGETplus SMAD7 siRNA (GE Dharmacon, Lafa-
yette, CO) and non-silencing siRNA was used as control
(GE Dharmacon) according to the manufacturer's protocol.
Final concentration of siRNA was 100 nM in 2 ml DMEM
medium supplemented with 1 % FBS. The cells were trans-
fected with siRNA for 72 h, washed and incubated with SF
medium for 48 h before adding 1 ng/ml IL-1α. The PSCs
were incubated for another 72 h and PSC supernatants
were harvested (5 days after removing siRNA from the
PSCs). The PSCs were lysed for protein and RNA experi-
ments and stored in −30 °C until use.
For the co-culture assays, 5×105 BxPC-3 cells were
seeded per Transwell® insert (pore size, 0,4 μm) (Corning
Incorporated, Corning, NY) and cultured for 24 h before
placing the inserts into 6-well plates containing a confluent
layer of either untreated, control siRNA or SMAD7 gene
silenced PSCs. Cancer cells and PSCs were co-cultured for
12 h before removing the insert. The PSCs were cultured
for further 60 h and PSC supernatants were harvested after
a total of 5 days after removing the siRNA. The PSCs were
lysed for protein and RNA experiments and stored at
−30 °C until use.
RNA extraction and real-time quantitative RT-qPCR
Total RNA was prepared from the samples using RNA Easy
Mini kit (Qiagen Inc, Valencia, CA) and cDNA was synthe-
sized with SuperScript III Reverse Transcriptase First-
Strand cDNA Synthesis kit according to the manufacturer’s
protocol (Life Technologies, Carlsbad, CA). Quantitative
PCR was performed with Platinum SYBR Green Master
Mix (Life Technologies) on 7900 Real-Time PCR system
with 7900 System SDS 2.3 Software (Life Technologies)
according to the manufacturer’s protocol. Specific primers
for SMAD2, SMAD3, SMAD7, IL-6, IL-8 and IL-1R1 (Life
Technologies) were used. Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) was utilized as housekeeping con-
trol gene. The primers were designed using Primer-BLAST
[33]. All reactions were performed in triplicates including
non-template controls. The results were analysed using the
ΔΔCt method [34]. The relative gene expression raw data
were normalized to GAPDH and presented as relative gene
expression for each gene.
ELISA analysis
The levels of IL-1α and TGFβ in supernatants from
PC013, BxPC-3, CAPAN2 cells and PSCs were assessed
after culturing the cells for 3 days in DMEM medium sup-
plemented with 1 % FBS. The supernatants were harvested
and the concentration of IL-1α (Biolegend, San Diego,
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CA) and TGFβ (Nordic BioSite, Oslo, Norway) were mea-
sured by ELISA according to the manufacturers’ protocol.
Immunocytochemistry and immunohistochemistry
Cultured PSCs were immunostained with anti-human
IL-1R1 antibodies (ab59995, ABcam, Cambridge, UK),
visualized by Alkaline Phosphatase Red (Biocare Medical,
Concord, CA) and DAPI (Jackson ImmunoResearch, West
Grove, PA) as described elsewhere [21]. Representative
PDAC tissue was stained for IL-1R1 (04–465, Merck
Millipore, Darmstadt, Germany) as described previously
[21]. Positive cells were detected with ImmPRESS™ HRP
Polymer Detection Kit (Vector laboratories, Peterborough,
UK).
Western blot analysis
Total cell lysates from PSCs grown to confluence in 12
well plates in the presence of either control medium,
TGFβ (2 ng/ml) and/or 10 μM SIS3, were prepared in
Laemmli buffer and electrophoresed on 12 % (w/v) poly-
acrylamide gels (acrylamide: N’N’-bis-methylene acry-
lamide 30:1). This was followed by protein electrotransfer
to nitrocellulose membranes and immunoblotting over
night with antibodies against, IL-1R1 (04–465, Merck
Millipore, Darmstadt, Germany), SMAD7 (MAB2029,
R&D Systems) and GAPDH (2118, Cell Signaling Tech-
nology, Boston, MA), respectively. Immunoreactive bands
were visualized using HRP conjugated secondary antibodies
(LI-COR, Lincoln, NE) and LumiGLO HRP Chemilumines-
cent Substrate (KPL Protein research Products, Gaithers-
burg, MD). Images were acquired using EpiChemi II
Darkroom (UVP, Upland, CA) and band intensity processed
using FIJI software as described by Schindelin et al. [35].
Migration assay
Cell migration was assessed using a scratch assay [36].
2×105 BxPC-3 cells in 100 μl DMEM medium supple-
mented with 10 % FBS were seeded in 12 well culture plates
pre-marked with three ink marks under the bottom of each
well. The cells were left to adhere for 2 h; then, 1 ml of
serum free medium (SF) was added, and the cells were incu-
bated overnight to confluence. A scratch was made with a
100 μl pipette tip. The marks under the dishes served to
ensure that exactly the same observation field was studied
during the observation period. After scratching, the cells
were washed twice with NaCl and then kept in SF medium
or PSC supernatants for 24 h. The scratch wounds were
observed in a Zeiss Axiovert 25 inverted microscope with a
5× objective (Carl Zeiss AS, Oslo, Norge). Images (each
1.4 × 1.0 mm), taken right after the addition of SF or PSC
supernatants and at 24 h, were obtained with a Zeiss
AxioCam ICc3 (Carl Zeiss AS). For each picture, the
wound area was measured by FIJI software as described
by Schindelin et al. [35]. Per cent wound closure was
calculated for the time point of observation based on the
mean of 2–3 observations from each scratch.
Statistical analysis
The statistical analysis was performed with GraphPad
Prism 5 (GraphPad Software), p < 0.05 was considered
statistically significant and error bars throughout indicate
standard error of the mean (SEM). Normalized data were
analysed by paired t-test, multiple comparisons were
analysed using ANOVA including Bonferroni correc-
tion and correlation determined by Pearson correlation
coefficient.
Results
TGFβ down-regulates the expression of IL-1R1 in
pancreatic stellate cells
Interleukin-1 receptor 1 (IL-1R1) is the exclusive receptor
for IL-1, and its expression level on a cell is a determinant
for signaling strength and biological response to IL-1
[37, 38]. High expression of IL-1R1 on cultured PSCs
was demonstrated by immunofluorescence (Fig. 1a).
Immunohistochemistry of intact PDAC tissue showed
expression of IL-1R1 in both stroma cells and cancer cells
(Fig. 1b). Several biological factors have been found to
modulate the effects of IL-1 by down-regulating or enhan-
cing the expression of IL-1R1 [39, 40]. We examined how
incubation of PSCs in the presence of IL-1α, platelet-
derived growth factor (PDGF), or TGFβ, influenced their
expression of IL-1R1. Figure 2a shows that in long-term
culture (3 days) of PSCs, a single addition of PDGF
(10 ng/ml) increased the expression of the IL-1R1 gene at
the mRNA level, while both IL-1α (1 ng/ml) and TGFβ
(2 ng/ml) strongly decreased the expression. The pro-
tein level of IL-1R1 was also significantly decreased upon
incubation with TGFβ as compared to untreated controls
(Fig. 2b). Further support for a role of TGFβ in down-
regulation of IL-1R1 in PSCs was obtained by the use of
A-83-01, a blocker of TGFβ type I receptor ALK5 kinase
activity, which inhibits SMAD2/3 activation. Thus, A-83-
01 abolished the inhibitory effects of TGFβ on IL-1R1
mRNA expression in PSCs (Fig. 2c). To investigate the
relative contributions of SMAD2 and SMAD3 we exa-
mined their expression in PSCs. As shown in Fig. 2d,
PSCs expressed high levels of SMAD3 and virtually no
SMAD2. To investigate the involvement of SMAD3 in
the down-regulation of IL-1R1, we incubated PSCs in the
presence of SIS3, a potent SMAD3 inhibitor, upon TGFβ
exposure. SIS3 abrogated the inhibitory effects of TGFβ
and kept the PSC expression of IL-1R1 close to the
control level (Fig. 2e-f ). Together, these results provide
support for a role of the TGFβ-SMAD2/3 pathway in the
down-regulation of IL-R1 expression in PSCs.
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TGFβ down-regulates IL-1α induced cytokine production
in pancreatic stellate cells
IL-1α stimulates cytokine production, including IL-6 and
IL-8 in PSCs [21]. Since TGFβ inhibits IL-1R1 expression
in PSCs, we next examined whether TGFβ affected IL-1α
stimulation of PSC cytokine production. TGFβ signifi-
cantly inhibited the effects of IL-1α on PSC expression of
IL-6 (Fig. 3a) and IL-8 (Fig. 3b).
SMAD7 is involved in the regulation of IL-1R1 expression
in pancreatic stellate cells
We measured the gene expression of SMAD7 and IL-1R1
in series of primary PSC cell preparations (n = 19) esta-
blished in culture from PDAC patients, and found a
significant (P = 0.038) correlation between SMAD7 and
IL-1R1 gene expression (Fig. 4a). TGFβ increased the level










Fig. 1 IL-1R1 expression in pancreatic stellate cells (PSCs) and PDAC tissue. a The expression and localization of IL-1R1 (red) were analysed by


















































































































Fig. 2 TGFβ down-regulates the expression of IL-1R1 in pancreatic stellate cells. a PSCs cultured in the presence of TGFβ, IL-1α or PDGF were analysed
by qPCR and IL-1R1 gene expression normalized to unstimulated PSCs. b Protein expression was measured 3 days after exposure to TGFβ and analysed
by western blotting. IL-1R1 was quantified by measuring the band intensity (n = 4). c IL-1R1 gene expression was analysed in PSCs incubated in the
presence of TGFβ (2 ng/ml) and the TGFβ signaling inhibitor, A-83-01 (5 μM). d PSC expression of SMAD2 and SMAD3 mRNA was assessed by qPCR.
e PSCs were stimulated for 3 days with TGFβ (2 ng/ml) in the presence or absence of the SMAD3 inhibitor, SIS3 (5 μM). The gene expression of IL-1R1
was quantified by qPCR and (f) protein expression visualized by western blotting. Error bars represent S.E.M.; *p < 0.05, ** p < 0.005, ***p < 0.001
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when the effects of TGFβ were tested over a range of
concentrations (30 pg/ml – 8 ng/ml), the upregulation of
SMAD7 expression and the down-regulation of IL-1R1
expression corresponded closely, appearing around 1 ng/
ml and being maximal at ≥ 2 ng/ml (Fig. 4b), suggesting a
potential role for SMAD7 in the regulation of IL-1R1
expression in PSCs. Finally, a relationship between SMAD7
and IL-R1 expression was further supported by experi-
ments which showed that silencing of SMAD7 expression,
using a SMAD7-specific siRNA (Fig. 4c), was associated
with reduced protein expression of IL-1R1 compared to the
controls (Fig. 4d). These results are consistent with a role
of SMAD7 as an enhancer of IL-1 signaling in PSCs due to
its attenuation of TGFβ.
Pancreatic adenocarcinoma cells inhibit the expression of
IL-1R1 on the stellate cells: Role of IL-1α and TGFβ
Further studies aimed at exploring some of the interac-
tions between PDAC cells and PSCs, focusing on the roles



















































Fig. 3 Pre-treatment with TGFβ inhibits IL-1α induced up-regulation of IL-6 and IL-8 in pancreatic stellate cells. The PSCs were incubated for 3 days
in the presence or absence of 2 ng/ml recombinant TGFβ before adding 1 ng/ml IL-1α to the cells. The expression of (a) IL-6 and (b) IL-8 mRNA
were measured by qPCR after 4 h of incubation. Error bars represent S.E.M.; ***p < 0.001
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Fig. 4 SMAD7 is involved in the regulation of IL-1R1 expression in PSCs. a Gene expression of SMAD7 and IL-1R1 from PSCs established from different
patients (n = 19) were analysed by qPCR. PSCs were transfected with non-signaling siRNA (control) or SMAD7 siRNA (100nM) for 3 days. Correlation
was determined using Pearson correlation coefficient. *p < 0.05. b Pancreatic stellate cells were incubated in the presence of increasing concentrations
of recombinant TGFβ (30 pg/ml – 8 ng/ml) to assess the optimal concentration required to down-regulate the gene expression of IL-1R1 and to
investigate the impact of TGFβ on PSC expression of SMAD7. c SMAD7 protein expression was visualized by western blotting after 3 days of culture
and (d) IL-1R1 was visualized after additional 2 days in serum free medium
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IL-1α and TGFβ in conditioned medium from PDAC cell
lines and from PSCs. BxPC-3 and PC013 produced IL-1α,
while conditioned medium from CAPAN2 and PSCs was
IL-1α negative. TGFβ was detected at similar high levels
in the conditioned medium from all the PDAC cell lines.
PSCs also produced TGFβ, but at lower levels compared
to the cancer cell lines (Table 1).
To investigate effects exerted by PDAC cells on IL-1R1
expression in PSCs, we co-cultured PSCs and the PDAC
cell lines PC013, BxPC-3, and CAPAN2. The presence of
either of these PDAC cell lines significantly reduced PSC
expression of IL-1R1 (Fig. 5a-c suggesting possible in-
volvement of paracrine signaling mechanisms acting
between the cancer cells and the PSCs. To examine the
role of IL-1α produced by the cancer cell lines, the co-
cultures were incubated in the presence of anakinra, a recom-
binant, non-glycosylated form of the human interleukin-1
receptor antagonist (IL-1RA). This increased the expression
of IL-1R1 in the PSCs and reduced the inhibitory effects
exerted by the IL-1α positive cancer cell lines PC013 and
BxPC-3 [21] (Fig. 5a-b), while the expression of IL-1R1 in
PSCs co-cultured with the PDAC cell line CAPAN2, which
is IL-1 negative [41], was not affected by the presence of
IL-1RA (Fig. 5c).
We next examined the possible involvement of TGFβ
from the cancer cells in the observed PDAC cell-induced
down-regulation of IL-1R1 expression in PSCs. To pre-
vent any direct effects of the TGFβ signaling inhibitors
(A-83-01 and SIS3) on the cancer cell lines, conditioned
media from PC013, BxPC-3 or CAPAN2 cells were added
to the PSCs and cultured in the presence or absence of
these inhibitors as an alternative to co-culture. All these
conditioned media suppressed IL-1R1 mRNA to varying
degrees (Fig. 5d-f). Either A-83-01 or SIS3 partly counter-
acted the down-regulatory effect of PC013-conditioned
medium on PSC expression of IL-1R1 (Fig. 5d) and
completely abolished the inhibition exerted by the media
obtained from CAPAN2 and BxPC-3 cells (Fig. 3e-f ).
It may be noted that in PSCs incubated with BxPC-3
conditioned medium, these TGFβ pathway inhibitors
significantly increased the expression of IL-1R1 compared
to unstimulated controls (Fig. 5e). Taken together, these
results suggest that both IL-1α, through an autoinhibitory
feedback, and TGFβ mediate PDAC cell-induced down-
regulation of IL-1R1 expression in PSCs.
TGFβ treatment of stellate cells reduces carcinoma cell
migration by inhibiting the stimulatory effects of IL-1α
We next investigated effects of PSCs on PDAC cells. Pre-
vious studies have demonstrated increased migration of
pancreatic cancer cells in the presence of PSCs [14]. To
study the involvement of IL-1α and TGFβ and the effects
exerted by PSCs on migratory activity of PDAC cells, we
assessed the effects of conditioned medium from unstimu-
lated and IL-1α-stimulated PSCs on migration of BxPC-3
cells in a wound closure model. The conditioned medium
from PSCs significantly increased the migration of the
carcinoma cells compared to control medium (Fig. 6a).
Moreover, conditioned medium from IL-1α-stimulated
PSCs further enhanced cancer cell migration compared to
both control medium and conditioned medium from un-
stimulated PSCs (Fig. 6b). This was not due to direct
effects of IL-1α or TGFβ, since wound closure assays on
BxPC-3 cells stimulated with IL-1α and TGFβ as single
agents or in combination showed no effects on migration
of BxPC-3 cells (Fig. 6c).
We also investigated whether the stimulatory effects of
IL-1α on the ability of PSCs to induce migration of
BxPC-3 cells was affected by TGFβ. Medium from PSCs
cultured in the presence of IL-1α and TGFβ, as single
agents or in combination, was added to the BxPC-3 cells
in the wound closure model. Conditioned medium from
TGFβ-stimulated PSCs showed no effects on BxPC-3
migration compared to medium from unstimulated PSCs.
On the other hand, conditioned medium from PSCs stim-
ulated with TGFβ in combination with IL-1α significantly
inhibited the migration of cancer cells compared to condi-
tioned medium from IL-1α stimulated PSCs (Fig. 7a-b).
Together this indicates an inhibitory role of TGFβ in PSC
IL-1 signaling, affecting the potential of PSCs to induce
cancer cell migration.
Silencing of SMAD7 reduces the capacity of stellate cells
to induce carcinoma cell migration
SMAD7-silenced PSCs were incubated in the presence or
absence of IL-1α, and the effect of PSC-conditioned
medium was assessed in a wound closure model using
BxPC-3 pancreatic carcinoma cells. Silencing of SMAD7
reduced the ability of IL-1α to enhance the stimulating
effect of PSC conditioned medium on the migration of the
carcinoma cells compared to conditioned medium from
non-silenced PSCs (Fig. 8a-b). In other experiments we
co-cultured SMAD7-silenced PSCs with the IL-1α-
positive BxPC-3 cell line and the conditioned medium
was then added to the BxPC-3 wound closure model. The
conditioned medium from the co-culture of BxPC-3 cells
Table 1 Production of IL-1α and TGFβ by PDAC cell lines and
pancreatic stellate cells
Cell type IL-1α pg/ml 105 cells TGFβ pg/ml 105 cells
BxPC-3 20.6 7553
CAPAN2 neg. a 7167
PC013 38.0 7448
PSC neg. a 4375
IL-1α and TGFβ levels were measured by ELISA in conditioned medium from
pancreatic cancer cell lines (PC013, BxPC-3, CAPAN2) and PSCs after 3 days of
culture. The results are presented in pg/ml/105 cells
aBelow the lower detection limit













































































































































































Fig. 5 TGFβ inhibitors reduce the inhibitory effects of cancer cells on PSCs expression of IL-1R1. a-c The pancreatic cancer cell lines; (a) PC013, (b)
BxPC-3 and (c) CAPAN2 were co cultured with PSCs in the presence of IL-1 receptor antagonist (IL-1RA) (10 µg/ml). d-f PSCs were cultured for 3 days
in serum free conditioned medium (CM) from (c) PC013, (e) BxPC-3 and (f) CAPAN2 cell lines and TGFβ signaling inhibited by A-83-01 (5 μM) and SIS3
(5 μM). The IL-1R1 gene expression was analysed in PSCs by qPCR and the result shown as relative expression normalized to GAPDH or unstimulated
controls. Error bars represent S.E.M.; *p < 0.05, **p < 0.005, ***p < 0.001
a b c
Fig. 6 IL-1α induces PSC-stimulated migration of BxPC-3 cells. BxPC-3 cells were cultured in colonies to confluence and scratch wounds were
established in the centre of the colony. The wound area was measured at 0 and 24 h and the data normalized to controls. a-b PSCs were cul-
tured in serum free conditions for 3 days in the presence or absence of IL-1α (1 ng/ml) and the conditioned medium was transferred to the
wound assays and incubated for 24 h. c Direct effects of TGFβ and IL-1α on BxPC-3 migration were analyzed by incubating BxPC-3 scratch
wounds in the presence of IL-1α (1 ng/ml) and TGFβ (2 ng/ml) as single agents and in combination. Error bars represent S.E.M.; *p < 0.05,
**p < 0.005, ***p < 0.001
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a b
Fig. 7 TGFβ inhibits cancer cell migration induced by IL-1α stimulated PSCs. a-b Conditioned medium harvested from PSCs cultured in the presence
of IL-1α (1 ng/ml) and/or TGFβ (2 ng/ml) (3 days) was transferred to BxPC-3 wound assays. Wound recovery was determined after 24 h and the data
normalized to unstimulated controls. Error bars represent S.E.M.; ***p < 0.001
a b
dc
Fig. 8 Inhibition of SMAD7 expression in PSCs reduces tumor stroma interactions and decrease cancer cell migration. a-b PSCs were transfected with
non-targeting siRNA (control) or SMAD7 siRNA (100nM) for 3 days, followed by 2 days incubation in serum free medium and another 3 days of culture
in the presence or absence of IL-1α (1 ng/ml) or (c-d) 12 h of indirectly co-culture with 5×105 BxPC-3 cells and additionally 60 h of culture without any
supplements. The supernatants were harvested 5 days post siRNA transfection and transferred to BxPC-3 scratch wound assays. Wound recovery was
determined after 24 h and the data was normalized to controls. Error bars represent S.E.M.; ***p < 0.001
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and SMAD7 silenced PSCs significantly inhibited the
migration of carcinoma cells compared to the conditioned
medium obtained from the co-culture of BxPC-3 and
non-silenced PSCs (Fig. 8c-d). This strongly suggests that
carcinoma cell migration is induced by IL-1α activation of
PSCs, which can be inhibited by SMAD7 depletion. To-
gether the data indicates a suppressive role for the TGFβ/
SMAD signaling pathway in tumor stroma interactions.
Discussion
In pancreatic adenocarcinoma the stroma forms the dom-
inating bulk of the tumor tissue [42]. The pancreatic stel-
late cell is a key player in the complex regulation of the
pancreatic tumor microenvironment [10]. IL-1α has pre-
viously been shown to activate PSCs and induce inflam-
matory responses in the tumor stroma [21]. TGFβ may
act as both a tumor suppressor and a tumor promotor in
pancreatic adenocarcinoma [43, 44]. In the present study
we provide evidence for the involvement of TGFβ and
SMAD in the regulation of IL-1 mediated responses in
PSCs, focusing on inhibition of PSC induced migration of
malignant cells.
In pancreatic adenocarcinomas, expression of TGFβ has
been found to be enhanced in the cancer cells within the
tumor mass, and overexpression of TGFβ was associated
with poor survival [45]. In the tumor stroma, PSCs have
also been demonstrated to produce TGFβ [46, 47]. We
have previously reported that IL-1α produced by pancre-
atic cancer cells can activate and sustain the expression of
inflammatory factors produced by PSCs [21] and promote
cancer cell migration [48]. It has also been shown in pan-
creatic cancer cells that IL-1α exerts strong stimulatory
effects on PSCs by inducing and sustaining a constitutive
NFkB activation, associated with a metastatic phenotype
[49, 50]. In the present study, we have demonstrated an
inhibitory role of TGFβ in the regulation of IL-1α signa-
ling between cancer cells and pancreatic stellate cells, with
subsequent inhibition of the ability of PSCs to enhance
cancer cell migration. We found that TGFβ reduced the
expression of IL-1R1 on PSCs which subsequently dimi-
nished their ability to stimulate cancer cell migration upon
IL-1α stimulation. The observation that TGFβ down-
regulates the expression of IL-1R1on PSCs has to our
knowledge not been reported previously. However, TGFβ
has been found to reduce surface receptor expression of IL-
1R1 in hematopoietic cells and T-cells, leading to reduced
potential of the cells to respond to IL-1 stimulation [51].
The inhibitory effects of TGFβ on PSC expression of
IL-1R1 was inhibited by blocking SMAD3, suggesting
involvement of the canonical, SMAD-dependent TGFβ
signaling pathway in the regulation of the IL-1R1 expres-
sion in these cells. SMAD7, an endogenous inhibitor of
SMAD signaling, has been found to be overexpressed in
pancreatic adenocarcinoma cells compared to healthy
pancreatic tissue [52], but its expression and role in hu-
man PSCs is not known. We found a positive correlation
between endogenous, unstimulated SMAD7 levels and
the expression of IL-1R1 in PSCs (Fig. 4a). However,
treatment of PSCs with TGFβ increased SMAD7 beyond
the basal, endogenous level concomitant with a decrease
in IL-1R1 (Fig. 4b). Notably, despite high levels of stimu-
lated SMAD7, there was no increase in IL-1R1, which
could be explained by negative feedback mechanisms at-
tenuating the TGFβ signal. Silencing of endogenous
SMAD7 reduced PSC expression of IL-1R1 and attenu-
ated the effects exerted by IL-1α on the ability of PSCs to
stimulate cancer cell migration. These results indicate
that endogenous expression of SMAD7, by its ability to
reduce the effect of TGFβ, is implicated in modulation of
IL-1 signaling in pancreatic stellate cells.
SMAD7 might be a target for inhibition of IL-1α-
dependent stimulation of pancreatic cancer cell migration.
Interestingly, in inflammatory bowel disease, silencing of
SMAD7 with anti-sense oligonucleotide treatment restored
SMAD3 activation and reduced synthesis of inflammatory
cytokines by endogenous TGFβ [53]. Our data showing a
relationship between SMAD7 and IL-1R1 expression in
PSCs is also consistent with recent data demonstrating de-
creased inflammation and clinical benefits for patients with
active Crohn’s disease after blocking SMAD7 by a SMAD7
anti-sense oligonucleotide [54]. On the other hand, a previ-
ous report by Lee et al. has suggested an anti-inflammatory
role of SMAD7 (and SMAD6) upon TGFβ treatment,
through binding to Pellino-1, an IRAK1 adaptor protein
which inhibits NFkB transcriptional activity and subse-
quently causes reduced expression of pro-inflammatory
genes [55]. However, the TGFβ level required to down-
regulate IL-1R1 is low compared to the levels required for
upregulating the expression of SMAD7, indicating that
different mechanisms are involved in the regulation of IL-
1R1 activity and NFkB activity. This is further supported by
several studies suggesting that Pellino 1 is dispensable for
IL-1R1 signaling [56].
Activation of PSCs by IL-1 is associated with a specific
inflammatory gene profile including chemokines, several
inflammatory cytokines and some growth factors [21, 57].
Together, these factors support tumor progression in vivo
and in vitro by enhancing tumor angiogenesis and cancer
cell proliferation and migration [48, 57]. IL-1α inhibition
by IL-1RA or IL-1α-neutralizing antibodies reduced the
inflammatory PSC profile and inhibited cancer cell migra-
tion [21, 48]. Our present findings are consistent with the
notion of a suppressing role for TGFβ/SMAD signaling in
the regulation of the inflammatory PSC profile induced by
IL-1α, with subsequent reduced migration of the carci-
noma cells. The complex cellular cross-talk within the
tumor stroma allows for the involvement of multiple sig-
naling pathways in the regulation of cancer cell migration.
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Recently, Oyanagi et al. demonstrated in a 3D migration
model that fibroblast-derived HGF level was reduced by
addition of TGFβ, with concomitant inhibition of migra-
tion of pancreatic cancer cells, suggesting a direct inhibi-
tory effect of TGFβ [58]. In our migration model no effect
on cancer cell migration was observed after incubating
PSCs in the presence of TGFβ alone, suggesting that other
factors must be involved for TGFβ to exert its inhibitory
effect on cancer cell migration. Furthermore, the existence
of a vast cellular heterogeneity in the stromal compartment
[59] might indicate diverse effects of TGFβ within the
same tumor.
While much evidence has suggested a role of the tumor
stroma as a supporter of pancreatic cancer progression,
therapeutic stroma-directed strategies have so far not been
successful [9], and recent experimental studies have actu-
ally raised doubt about the whole concept [60]. Depletion
of pancreatic carcinoma-associated fibroblasts in geneti-
cally engineered mice has been found to accelerate disease
progression [15, 16]. Taken together, the conflicting data
[9, 12–16] indicate a more complex situation than has
hitherto been recognized and which should be inves-
tigated in even more detail. More studies are needed to
explore further the properties of pancreatic stellate cells,
their interaction with the carcinoma cells, and the effects
of the factors that regulate these cells.
Conclusion
In the current work, we explored the role of the TGFβ-
SMAD3 signaling pathway in pancreatic stellate cells and
the consequences for tumor-stroma interactions and pan-
creatic adenocarcinoma cell migratory activity. We found
that TGFβ down-regulated the expression of IL-1R1 on the
stellate cells, which resulted in inhibition of the responses
to IL-1α, with loss of the stimulatory effect of IL-1α on the
ability of pancreatic stellate cells to enhance migration of
the pancreatic carcinoma cells. Furthermore, depletion of
SMAD7 upregulated the effects of TGFβ and reduced the
expression of IL-1R1, leading to reduced stellate cell
enhancement of carcinoma cell migration. There is a need
to critically reassess the complexity of cross-talk between
malignant and non-malignant cells of the pancreatic tumor.
It might be of interest to explore SMAD7 in the stellate
cells as a potential therapeutic target.
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